Skip to main content
Premium Trial:

Request an Annual Quote

ZaBeCor, Biothorpe Pharmaceuticals, Rosetta Genomics, Isis Pharmaceuticals, Alnylam Pharmaceuticals, Regulus Therapeutics, MDRNA, Nasdaq Stock Exchange

Premium
ZaBeCor Forms Subsidiary to Focus on Cancer
 
Private RNAi drug developer ZaBeCor said this week that it has formed a subsidiary called Biothorpe Pharmaceuticals to develop siRNAs, antisense compounds, and other molecular technologies as treatments for cancer.
 
ZaBeCor was founded in 2002 using technology licensed from the University of Pennsylvania, including the use of siRNAs against an intracellular kinase called Syk that is associated with numerous inflammatory responses (see RNAi News, 6/8/2006).
 
According to the company, Syk kinase is also required for cellular proliferation in several cancers. As such, the company intends to license its intellectual property to Biothorpe for use in developing treatments for acute myelogenous leukemia, B cell lymphoma, and chronic lymphocytic leukemia.
 
ZaBeCor will continue to focus on inflammatory disorders, it added.
 

 
Rosetta Liver Cancer Partnership with Isis Transferred to Regulus
 
Rosetta Genomics this week announced that its collaboration with Isis Pharmaceuticals to develop a miRNA-targeting treatment for liver cancer has been transferred to Regulus Therapeutics, a miRNA joint venture between Isis and Alnylam Pharmaceuticals.
 
According to Rosetta, the arrangement will continue under the same terms and conditions of the original deal (see RNAi News, 2/23/2006).
 

 
MDRNA Stock Fails to Meet Nasdaq Listing Requirement
 
MDRNA said this week that it has received a notice from the Nasdaq Stock Market that its stock has failed to comply with the exchange’s minimum bid price requirement after trading below $1 per share for 30 consecutive days.
 
As a result, the shares could be delisted.
 
The company said it has 180 days to regain compliance, which requires that the stock trade at or above the $1 for a minimum of 10 consecutive days.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.